Baird, L, Teagarden, R, Unger, T, Hirsch, G. New medicines eight years faster to patients: Blazing a new trail in drug development with adaptive licensing. 2013. http://goo.gl/RL1dfZ (accessed March 31, 2014).
Baird, LG, Trusheim, MR, Eichler, H-G, Berndt, ER, Hirsch, G. Comparison of stakeholder metrics for traditional and adaptive development and licensing approaches to drug development. Ther Innov Regul Sci. 2013;47:474–483.
Boon, WPC, Moors, EHM, Meijer, A, Schellekens, H. Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe. Clin Pharmacol Ther. 2010 Dec;88:848–853.
Carlson, JJ, Sullivan, SD, Garrison, LP, Neumann, PJ, Veenstra, DL. Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010;96:179–190.
Chang, M, Chow, S-C, Pong, A. Adaptive design in clinical research: Issues, opportunities, and recommendations. J Biopharm Stat. 2006;16:299–309; discussion 311-312.
Dreyer, NA, Tunis, SR, Berger, M, et al.
Why observational studies should be among the tools used in comparative effectiveness research. Health Aff (Millwood). 2010;29:1818–1825.
Eichler, H-G, Oye, K, Baird, LG, et al.
Adaptive licensing: Taking the next step in the evolution of drug approval. Clin Pharmacol Ther. 2012;91:426–437.
Eijkenaar, F, Emmert, M, Scheppach, M, Schöffski, O. Effects of pay for performance in health care: A systematic review of systematic reviews. Health Policy. 2013;110:115–130.
Faulkner, E, Annemans, L, Garrison, L, et al.
Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: A report of the ISPOR Personalized Medicine Special Interest Group. Value Health. 2012;15:1162–1171.
Gerber, A, Stock, S, Dintsios, CM. Reflections on the changing face of German pharmaceutical policy: How far is Germany from value-based pricing?
Henshall, C, Mardhani-Bayne, L, Frønsdal, KB, Klemp, M. Interactions between health technology assessment, coverage, and regulatory processes: Emerging issues, goals, and opportunities. Int J Technol Assess Health Care. 2011;27:253–260.
Henshall, C, Schuller, T, HTAi Policy Forum. Health technology assessment, value-based decision making, and innovation. Int J Technol Assess Health Care. 2013;29:353–359.
Henshall, C, Schuller, T, Mardhani-Bayne, L. Using health technology assessment to support optimal use of technologies in current practice: The challenge of “disinvestment.”
Int J Technol Assess Health Care. 2012;28:203–210.
Husereau, D, Goeree, R, Tsoi, B, Masucci, L, Campbell, K. WHO Pan American Health Organization/Organización Panamericana de la Salud (PAHO/OPS): Synthesis of payer (HTA bodies) / regulator interactions for drugs and medical devices. 2013. http://dl.dropboxusercontent.com/u/27573264/DRAFT_18_Sep_Husereau_v2_Clean.pdf (accessed March 31, 2014).
Hutton, J, Trueman, P, Facey, K. Harmonization of evidence requirements for health technology assessment in reimbursement decision making. Int J Technol Assess Health Care. 2008;24:511–517.
Kanavos, P, Reinhardt, U. Reference pricing for drugs: Is it compatible with U.S. health care?
Health Aff (Millwood). 2003;22:16–30.
Klemp, M, Frønsdal, KB, Facey, K, HTAi Policy Forum. What principles should govern the use of managed entry agreements?
Int J Technol Assess Health Care. 2011;27:77–83.
Kreis, J, Schmidt, H. Public engagement in health technology assessment and coverage decisions: A study of experiences in France, Germany, and the United Kingdom. J Health Polit Policy Law. 2013;38:89–122.
Mello, MM, Goodman, SN, Faden, RR. Ethical considerations in studying drug safety–The Institute of Medicine report. N Engl J Med. 2012;367:959–964.
Role of pharmacoeconomic analysis in R&D decision making - When, where, how?
Norman, G. Commentary: Breaking the mold of normative clinical decision making: Is it adaptive, suboptimal, or somewhere in between?
Acad Med J Assoc Am Med Coll. 2010;85:393–394.
Rabinovich, M, Wood, F, Shemer, J. Impact of new medical technologies on health expenditures in Israel 2000-07. Int J Technol Assess Health Care. 2007;23:443–448.
Rawlins, M. De testimonio: On the evidence for decisions about the use of therapeutic interventions. Lancet. 2008;372:2152–2161.
Salvatore, D, Buzzetti, R, Baldo, E, Furnari, ML, Lucidi, V, Manunza, D, et al.
An overview of international literature from cystic fibrosis registries. Part 4: Update 2011. J Cyst Fibros. 2012;11:480–493.
Tsoi, B, Masucci, L, Campbell, K, et al.
Harmonization of reimbursement and regulatory approval processes: A systematic review of international experiences. Expert Rev Pharmacoecon Outcomes Res. 2013;13:497–511.
Walker, S, Sculpher, M, Claxton, K, Palmer, S. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. Value Health. 2012;15:570–579.
Evidence vs. access: Can twenty-first-century drug regulation refine the tradeoffs?
Clin Pharmacol Ther. 2012;91:378–380.